Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Molecular Markers Webinar Part 3: Panel Discussion Debating Who to Test and What to Test For
Dr West
Author
Howard (Jack) West, MD

Here is the next portion of our special webinar on molecular markers in advanced NSCLC, featuring Drs. Charlie Rudin from Johns Hopkins,  Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Glen Goss from the University of Ottawa and NCI-Canada's Lung Cancer Committee.   

In this continuing portion of the program, we have a debate on the merits of uniform vs. more selective testing of "druggable" mutations and consider whether it is more attractive to test for multiple markers simultaneous or perhaps sequentially, since they are typically mutually exclusive.  We also discuss the challenge of the delays in treatment that may become a real clinical problem for some patients if testing may require a few weeks of downtime.

Below you'll find the audio and video versions of the podcast, along with the transcript and figures for this activity.

[powerpress]

Molecular Markers SM Pt 3 Panel Discussion Audio Podcast

Molecular Markers SM Pt 3 Panel Discussion Transcript

Molecular Markers SM Pt 3 Panel Discussion Figs

We'll continue this rather intense discussion in the next podcast, coming soon.

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on